Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Excelerate Energy raises quarterly dividend to $0.09 a share

Excelerate Energy raises quarterly dividend to $0.09 a share

ReutersReuters2026/07/30 20:38
  • Excelerate Energy declared a quarterly cash dividend of $0.09 per Class A share for the quarter ended June 30, 2026.
  • Dividend marks an approximately 13% increase from the prior quarter.
  • Payable Sept. 3, 2026, to holders of record as of Aug. 19, 2026.
  • Operating subsidiary Excelerate Energy Limited Partnership set a corresponding $0.09 per-interest distribution on the same date.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Excelerate Energy Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260730921157) on July 30, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage